- Page 2/2
- Next Page
BUY
A recent past pick. They're in the helium business, used more in tech. The price of helium will continue to rise. They've made nice acquisitions recently., This morning they announced their private placement which will shore up their balance sheet. The stock made new highs after his pick, then sold off due to a short seller. Share are up sharply today, and he bought today. The stock can keep moving up.
Energy
BUY
Was a past pick a while ago. Still owns and likes it. He remains positive about the energy sector. Tamarack are great operators. They have lower decline rates and steady production rates. They bought Clearwater which will take time to integrate, but will add strongly to their manufacturing levels.
oil
gas
BUY
An old past pick. It's been frustratingly lately and doesn't know why. Everything is firing on all cylinders--there's more purchasing from all provinces, input costs for THC and CBD continue to drop. They're using up their older distillate at higher prices, but next their lower-priced distillate will get absorbed into the price and will increase their margins. The cannabis sector, after a slump, is on the cusp of rising again. Maybe NDVA will post positive earnings this year, which is rare for cannabis in Canada.
agriculture
PAST TOP PICK
(A Top Pick Jul 02/20, Down 2%) They have a proprty in Mexico they're consolidating, containing historic drill holes that they're re-drilling to get them to meet today's regulatory standards, and seeing the same or better results. Expects a major to scoop them up one day as a high-grade, low-cost silver mine. Continues to own and like it. He's selective about mining.
Mining
PAST TOP PICK
(A Top Pick Jul 02/20, Up 72%) A US medical device company (lifts, oxyegen and other homecare products). Continues to like it, given aging demographics. The valuation is attractive. They continue to grow by acqusition, adding geographic regions and fragmented, small busineses. They have cash to buy more companies and are EBIDTA positive. Good cash flow. Expects this to get taken out one day. Price pressures are always a possibility if suppliers raise prices. Also there are reimbursement cuts in the U.S. medical system every few years, another caveat.
Healthcare
PARTIAL SELL
It's trading at a premium to the Brookfield offer, so hold or sell? Whether to sell or hold depends on your individual weighting in your portfolio. If share price drops, will it hurt your portfolio? Maybe sell part of it now, then see if a higher bidder comes, which the market is waiting for.
oil pipelines
BUY
A past top pick. Still likes it for being in the renewable natural gas industry. Governments are forcing more RNG in the pipelines in the coming decade which Xebec has the expertise to do. A few quarters ago, management guided higher, but they missed, so the stock plunged. He was stopped out. Shares are about to rise again, based on his metrics. Hold if you own. This has a long future, of 5-15 years of tailwind.
INDUSTRIAL PRODUCTS
BUY
A past recommendation. There's been a sideways consolidation, yet managers are executing perfectly with acquisitions, then cross-selling old with new products to generate organic growth with acquisition growth. Valuation is cheap. It's pulled back and gone sideways this year, but he expects it to rise again.
chemicals
WATCH
They're in retail. Have a deal with ATD'B to take a bigger ownership position. Investors have forgotten about the retailers, which is a fragmented but strong business. FF has buying power. He used to own this, but is watching this. He expects the weed sector to revive. Expects ATD'B to take this over eventually.
Healthcare
WATCH
A past top pick. It's a smaller version of Xebec, both in renewable natural gas, but got dragged down by Xebec's woes and Covid. He got stopped out of this, but is happy to reconsider it. There's a 5-15-year tailwind for this sector as governments legislate for more energy.
Financial Services
TOP PICK
Telemedicine plus they use AI in their medical clinics. They make acquisitions to synergize and they grow organically. They boast $130 in revenue and $50 million in cash, so they can continue to buy more companies. It trades at 2.5x revenue vs.peers at 6x. Expect good multiple appreciation. Managers own a lot of stock and he's known them from the start. They execute well. They should rise a lot higher. (Analysts’ price target is $3.96)
Healthcare
TOP PICK
No price target A new company. The CEO comes from an orthotics company that he grew from $100 million to $600 million over six years until he sold it. Non-surgical devices have IP protection. They make small acquisitions and are talking to 50 small companies before they close these deals. He expects $55 revenues, but bigger deals will push that to $75-80 million. Trades at 1.2x revenues vs. peers' 4.5x-18x. Will grow by acquisition and organically as they expand into Europe.
Healthcare
TOP PICK
E-cars were a super hot trend. GPV make e-cars like cutaway vans and schoolbuses. They use a wireless charging technology, so vehicles can always be charging. Biden wants to phase out gas buses by 2025, so this a big opportunity. GPV numbers of last night aren't EBITDA-positive, but will be EBITDA positive later this year or next (after higher car production) which is rare in the e-car space. GPV flies under the radar, but also trades on the Nasdaq, so they have cash to allow them to grow. (Analysts’ price target is $53.08)
0
